VRX Stock Ownership Activity

VALEANT PHARMACEUTICALS INTL 13F holders

No value investing guru has made any change to the VALEANT PHARMACEUTICALS INTL (VRX) position according to the gurus' latest SEC quarterly report(s).

Which gurus or hedge funds are buying VRX now?

According to the latest SEC filing(s) VALEANT PHARMACEUTICALS INTL (VRX) has not been purchased by any super investor.

To see more about who is investing in VALEANT PHARMACEUTICALS INTL (VRX), please go to the VRX ownership page.

History
Name
Company
%
Activity
Share
Change
% change to
Portfolio
% of
Portfolio
2013 Q4 (5 results)
Nathaniel Simons
Meritage Group
+28.97%
+291,867
+1.26%
4.77%
Stephen Mandel
Lone Pine Capital
-0.32%
-25,222
-0.01%
4.17%
Quincy Lee
Ancient Art (Teton Capital)
-4.63%
-7,000
-0.19%
3.94%
Ole Andreas Halvorsen
Viking Global Investors
-6.93%
-620,604
-0.34%
4.56%
Glenn Greenberg
Brave Warrior Advisors
-7.00%
-285,424
-2.21%
18.22%
AVG reported price*: $117.40
2013 Q3 (3 results)
Glenn Greenberg
Brave Warrior Advisors
-1.26%
-83,862
-0.39%
30.77%
Stephen Mandel
Lone Pine Capital
-2.88%
-193,872
-0.11%
3.20%
Ole Andreas Halvorsen
Viking Global Investors
-5.72%
-390,706
-0.31%
3.71%
AVG reported price*: $104.33
2013 Q2 (6 results)
Stephen Mandel
Lone Pine Capital
buy
+8,012,507
+3.48%
3.48%
Ole Andreas Halvorsen
Viking Global Investors
buy
+9,492,256
+4.54%
4.54%
Jeffrey Ubben
ValueAct Holdings
buy
+18,923,877
+16.74%
16.74%
Glenn Greenberg
Brave Warrior Advisors
buy
+6,657,451
+26.53%
26.53%
Nathaniel Simons
Meritage Group
buy
+1,185,229
+3.46%
3.46%
Quincy Lee
Ancient Art (Teton Capital)
buy
+151,295
+3.56%
3.56%
AVG reported price*: $86.08
14 of 108

Shares, change to shares, sold shares - split-adjusted.

Reported price - this doesn't represent the actual buy or sell price.
It is the split-adjusted price of the security as of the last day of the reported period.

Value or Price - If the security is completely sold out, we show the reported value (or price) prior to the actual period.